Filter your results
- 2
- 1
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsAnnals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩
Journal articles
hal-03623367v1
|
||
|
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortESMO Open, 2021, 6 (3), pp.100114. ⟨10.1016/j.esmoop.2021.100114⟩
Journal articles
hal-03273275v1
|
||
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsAnnals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩
Journal articles
hal-03376715v1
|